Status:
ENROLLING_BY_INVITATION
The Galleri® Community Research Program
Lead Sponsor:
GRAIL, Inc.
Conditions:
Data Collection
Eligibility:
All Genders
Brief Summary
GRAIL, the company that developed the Galleri test and is sponsoring this study, would like to learn more from individuals who have received the Galleri multi-cancer early detection test. The purpose...
Eligibility Criteria
Inclusion
- Have received the Galleri test prescribed by a provider per clinical care
- Capable of giving signed and legally effective informed consent. Consent provided by a legally authorized representative is not permitted in this protocol.
- Have signed HIPAA authorization(s)\* form for their medical records to be released and used for this study.
Exclusion
- Patients are excluded from the study if the patient is a GRAIL employee or contractor.
- Patients who have received the Galleri test in a GRAIL-sponsored research setting (i.e., clinical trial) are excluded.
Key Trial Info
Start Date :
August 19 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06603259
Start Date
August 19 2024
End Date
December 1 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GRAIL
Menlo Park, California, United States, 94025